Full Description
This book delves into the management of hepatocellular carcinoma (HCC) in low to middle-income countries. Shockingly, a projected 1.3 million people are at risk of dying from liver cancer by 2040, marking a 56.4% increase from 2020. HCC cases and deaths are expected to rise by over 50% in the next two decades.
The book discusses HCC management in low to middle-income countries with limited healthcare budgets and resources as the cost of therapeutic options for HCC, such as liver resection, transplantation, ablative therapies, transarterial embolotherapy/radiotherapy, systemic therapy, and palliative care vary significantly and can be substantial.
The book also emphasizes the role of the prevention of HCC. It is suitable for specialists in surgical oncology, medical oncology, radiation oncology, hepatology, gastroenterology, interventional radiology and surgery. It is also relevant for specialists in general medicine, public health, epidemiology, family medicine besides medical students, trainees and specialized nurses.
It aligns with UN SDG 3 - Good Health and Well-Being.
Contents
Introduction: Global burden of hepatocellular carcinoma (HCC).- Hepatocellular carcinoma epidemiology.- Molecular basis for hepatocellular carcinoma (HCC).- Hepatocellular carcinoma (HCC) carcinogens.- Hepatocellular carcinoma (HCC) diagnosis and stratification.- Surgical interventions for hepatocellular carcinoma (HCC) management.- Interventional Radiology methods for hepatocellular carcinoma (HCC) management.- Systemic therapy for hepatocellular carcinoma (HCC).- Palliative therapy and supportive care for hepatocellular carcinoma (HCC).- Prevention of hepatocellular carcinoma (HCC).- Future Prospects and unmet needs in hepatocellular carcinoma (HCC) management.
